Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has shared an update.
MindBio Therapeutics Corp. has made a groundbreaking discovery in using machine learning and AI to analyze patients’ speech for monitoring psychedelic microdosing adherence. This innovation not only strengthens MindBio’s intellectual property repository but also enhances its competitive edge in ensuring proper dosage and preventing misuse. Further advancing its technological capabilities, MindBio plans to acquire Life AI Corp Pty Ltd, whose smartphone-based application detects alcohol intoxication through speech analysis. This acquisition aligns with MindBio’s strategic expansion into using speech technology for broader health monitoring applications.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical stage biopharmaceutical company specializing in psychedelic microdosing. The company focuses on developing digital and AI technologies to enhance the precision and administration of its lead drug candidate, MB22001, within the mental health industry.
YTD Price Performance: -25.00%
Average Trading Volume: 110,818
Technical Sentiment Consensus Rating: Buy
For an in-depth examination of MBIO stock, go to TipRanks’ Stock Analysis page.